Precision NanoSystems Receives NRC-IRAP Funding to Support Development of the NanoAssemblr Nanoparticle Manufacturing Platform

Press Release

May 18, 2011

Precision NanoSystems, a provider of innovative tools for the development and manufacture of best-in-class nanoparticles for use as medicines, and in medical research, was awarded $47,000 by the National Research Council’s Industrial Research Assistance Program (NRC-IRAP) to support the development and optimization of scale-up processes for the manufacture of bioactive nanoparticles.

Precision NanoSystems CEO James Taylor, Ph.D. commented, “Precision would like to thank NRC-IRAP and particular our ITA, Graham North for their help, advice and ongoing support as we develop our prototype products towards commercialization. This award will support the development of a crucial aspect of our technology and is essential in order for us to maximize the value of this technology for Precision and Canada.”

About Precision NanoSystems, Inc.

At Precision NanoSystems we are creating innovative tools for the development and manufacture of best-in-class nanoparticles for use as medicines, and in medical research. Our proprietary NanoAssemblr platform enables the simple, rapid, reproducible, and scalable manufacture of next-generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to difficult-to-access cells and tissues in the body. We provide instruments, reagents and services to life sciences researchers and build strategic collaborations to revolutionize healthcare through nanotechnology. To join the revolution visit our website.

About NRC-IRAP 

The National Research Council – Industrial Research Assistance Program (NRC-IRAP) is Canada’s premier innovation assistance program for small and medium-sized enterprises (SMEs). It is a vital component of the NRC,a cornerstone in Canada’s innovation system, regarded world-wide as one of the best programs of its kind. For more information:http://www.nrc-cnrc.gc.ca/eng/ibp/irap.html


IN THE NEWS

Press Release

As a New Exporter finalist, PNI has demonstrated rapid growth in product exports globally. Although Canada and the US figure prominently in PNI’s portfolio, the technical sales team has also developed Australia, Asia, the Middle East and Euro...

Read More


Press Release

CanSinoBIO will license in Precision NanoSystems' proprietary RNA vaccine platform technology. Precision NanoSystems will lead RNA vaccine formulation development. CanSinoBIO will lead COVID-19 antigen design, pre-clinical testing and clinical trials

Read More